Jump to main content
Jump to site search

Vanadocene dichloride inhibits cell proliferation by targeting Aurora B


Vanadocene dichloride (VDC) was shown to exhibit antitumor properties against a wide spectrum of tumor cell lines. Many studies have been done to reveal the bioactivities of VDC and the interaction mechanism of VDC with biological molecules in test tube. One of the bioactivities of VDC is to arrest cell cycle in G2/M phase. However, its underline mechanisms of action and cytotoxicity profile are still not fully understood. HeLa cells were used in this study, and the IC50 of VDC was 8.61 µM with a 24-hour treatment. We used immunofluorescence staining method to analyze the morphology of cells in mitosis stage to elucidate what defects caused cells to arrest in mitosis. The chromosomal misalignment was found to be the major phenotype. One of the proteins responsible for chromosome alignment at metaphase is Aurora B kinase. Results of immunoblotting assay showed that Aurora B kinase activity was inhibited by VDC treatment. More than 50% of the Aurora B activity was inhibited when cells were treated with VDC in the concentration of 6.25 µM. That VDC was able to induce defects of chromosomal alignment in metaphase by inhibiting the activity of Aurora B kinase is an important mechanism of VDC to be developed as an antitumor agent.

Back to tab navigation

Publication details

The article was received on 19 Apr 2018, accepted on 12 Jul 2018 and first published on 13 Jul 2018

Article type: Paper
DOI: 10.1039/C8MT00089A
Citation: Metallomics, 2018, Accepted Manuscript
  •   Request permissions

    Vanadocene dichloride inhibits cell proliferation by targeting Aurora B

    T. Ting, M. Chang, T. Hsu, W. Wang, Y. Hsieh and C. Chang, Metallomics, 2018, Accepted Manuscript , DOI: 10.1039/C8MT00089A

Search articles by author